VRN 101099
Alternative Names: VRN-10; VRN-101099Latest Information Update: 11 Dec 2025
At a glance
- Originator Voronoi
- Class Antineoplastics; Small molecules
- Mechanism of Action ERBB 2 receptor antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 22 Oct 2025 Pharmacodynamics data from preclinical trials in Solid tumours presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-2025)
- 22 Oct 2025 Pharmacokinetics, efficacy and adverse events data from phase I clinical trials in Solid tumours presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-2025)
- 25 Apr 2025 Phase-I clinical trials in Solid tumours (First-line therapy, Metastatic disease) in South Korea (PO)